Zimmer Biomet Holdings, Inc. is a medical technology company that designs, manufactures, and markets orthopedic reconstructive products, sports medicine, biologics, extremities and trauma products, craniomaxillofacial and thoracic products, bone cement, surgical products, and integrated digital and robotic technologies. The company operates through three regional segments: the Americas, Europe, Middle East and Africa, and Asia Pacific. Key brands include Persona Knee, NexGen Knee Implants, Vanguard Knee, Oxford Partial Knee, ROSA Robot, Z1 Triple Taper Hip System, and HAMMR Automated Hip Surgical Impactor System. Zimmer Biomet serves orthopedic surgeons, neurosurgeons, healthcare institutions, and distributors globally. The company was incorporated in 2001, with its history dating to 1927, and acquired Biomet, Inc. in 2015.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage zimmerbiomet.com
Sector Healthcare IR page investor.zimmerbiomet.com
Tags
orthopedic implants, joint replacement, sports medicine, robotic surgery, bone cement, craniomaxillofacial, trauma care, biologics, digital health, artificial intelligence, Persona Knee, NexGen Knee Implants, Vanguard Knee, Oxford Partial Knee, ROSA Robot, Z1 Triple Taper Hip System, HAMMR Automated Hip Surgical Impactor System, ZBEdge Dynamic Intelligence, Persona OsseoTi Keel Tibia, Biomet Inc.
Press page investor.zimmerbiomet.com/news-and-events/news

Metrics

Valuation  
Market cap $ 16.811B
Market cap (USD) $ 16.811B
P/E 22.43
PEG 0.65
P/BV 1.32
P/S 1.96
P/OCF 8.92
P/FCF 10.23
Dividend yield 1.1%
Turnover / mcap —
Returns  
ROE 5.6%
ROI 3.5%
ROIC 4.6%
Profit margin 8.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 34.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 59.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 28
Quality score 5.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 8.232B 7.679B 7.394B 6.94B 7.836B 7.025B 7.982B 7.933B 7.824B 7.684B 5.998B 4.673B 4.623B 4.472B 4.452B 4.22B 4.095B 4.121B 3.898B 3.495B 3.286B 2.981B 1.901B 1.372B 1.179B 1.041B
Net profit 705.1M 903.8M 1.024B 231.4M 401.6M -138.9M 1.132B -379.2M 1.814B 305.9M 147M 720.1M 761M 755M 760.8M 596.9M 717.4M 848.6M 773.2M 834.5M 732.5M 541.8M 346.3M 257.8M 149.8M 176M
Free cash flow 1.473B 1.296B 1.291B 1.168B 1.327B 1.087B 1.379B 1.585B 1.426B 1.448B 649M 907.9M 863.1M 1.037B 1.063B 1.114B 1.012B — — — — — — 186.5M 117.1M 203.4M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 89.92 105.63 121.7 127.5 127.04 154.09 149.68 103.72 120.67 103.2 102.59 113.42 93.19 66.66 53.42 53.68 59.12 40.46 — — — — — — — —
Price performance 12m -0.15 -0.13 -0.05 0 -0.18 0.03 0.44 -0.14 0.17 0.01 -0.1 0.22 0.4 0.25 -0 -0.09 0.46 — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.6B 1.49B 1.28B 1.36B 1.45B 1.4B 1.38B 1.44B 1.48B 1.7B
↳ YoY growth +10.9% -6.8% -14.6% +6.9% +6.5% -3.3% -1.7% +4.4% +2.7% +15.1%
↳ 5y CAGR +13.8% +11.1% +6.4% +8.4% +0.1% -2.6% -1.6% +2.5% +1.7% +3.2%
Borrowings, current (USD) 576M 1.23B 525M 1.5B 500M 1.61B 544M 900M 863M 587M
Borrowings, non-current (USD) 10.7B 8.92B 8.41B 6.72B 7.63B 5.46B 5.15B 4.87B 5.34B 6.93B
Lease liabilities (USD) — — 283M 280M 293M 290M 220M 227M 243M 233M
Cash and deposits (USD) 634M 524M 543M 618M 802M 479M 376M 416M 526M 592M
Intangible assets (USD) 8.79B 8.35B 7.68B 7.26B 7.06B 6.3B 5.06B 4.86B 4.6B 4.72B
Right-of-use assets (USD) — — 275M 267M 275M 271M 196M 204M 214M 204M
Net debt (borrowings + leases - cash) (USD) 10.6B 9.62B 8.4B 7.88B 7.62B 6.88B 5.54B 5.58B 5.92B 7.16B
Cash flow detail
Operating cash flow (USD) 1.63B 1.58B 1.75B 1.59B 1.2B 1.5B 1.36B 1.58B 1.5B 1.7B
Purchases of property, plant and equipment (USD) -185M -156M -163M -207M -118M -172M -188M -291M -204M -225M
Purchases of intangible assets (USD) — — — — — -8.4M -29.7M -86.4M -153M -52.4M
Change in receivables (cash effect) (USD) -138M 177M 214M -93.8M -70M -15.1M -185M -51.9M -89.7M -127M
Change in inventories (cash effect) (USD) 76.4M -123M -200M -125M -40.8M 18.8M -75.6M -240M 49.9M 98.2M
Change in payables (cash effect) (USD) 28.7M -148M 156M -42M -95.1M 76.4M 103M -55.3M -322M 102M
Dividends paid (cash effect) (USD) -188M -194M -195M -197M -199M -200M -201M -201M -196M -190M
Share buybacks (cash effect) (USD) -416M — — — — — -126M -692M -868M -487M
Interest paid (cash effect) (USD) -363M -318M -283M -227M -193M -219M -162M -201M -201M -298M
Income taxes paid (cash effect) (USD) -270M -267M -237M -193M -147M -273M -327M -215M -329M -377M
Share-based compensation (USD) 57.3M 53.7M 65.5M 84.3M 79.7M 85.3M 105M 99.8M 101M 90.2M
Operating cash flow before change in receivables (USD) 1.77B 1.41B 1.53B 1.68B 1.27B 1.51B 1.54B 1.63B 1.59B 1.82B
Free cash flow (OCF - PPE - intangibles) (USD) 1.45B 1.43B 1.58B 1.38B 1.09B 1.33B 1.17B 1.2B 1.14B 1.42B
Income detail
Research and development expense (USD) 366M 367M 392M 449M 372M 497M 406M 459M 437M 459M
↳ 5y CAGR +8.9% +10.2% +13.9% +19.0% +6.7% +6.3% +2.0% +3.2% -0.5% +4.3%
Total comprehensive income (USD) 200M 2.16B -441M 1.08B -193M 468M 223M 1.01B 832M 762M
Comprehensive income to owners (USD) 200M 2.17B -441M 1.08B -195M 468M 223M 1.01B 832M 762M
Reported Mar 1, 2017 Feb 27, 2018 May 6, 2019 Feb 21, 2020 Feb 22, 2021 Feb 23, 2024 Feb 25, 2025 Feb 23, 2024 Feb 25, 2025 Feb 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery

Nov 06, 2026

Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery

​

New Category Will Introduce a Closed-Loop Framework: Predict. Perform. Recover. Keeping the Surgeon's Expertise and Control at the Center of the OR

DALLAS, Nov. 6, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today will announce Surgeon-Guided Autonomy, a new technology category representing the company's vision for the next era of intelligent orthopedic surgery.

Experience the full interactive Multichannel News Release here: https://www.multivu.com/zimmer/9427151-en-zimmer-biomet-introduces-surgeon-guided-autonomy-new-category-intelligent-surgery

Your browser does not support the video tag.

Built on a simple principle: transfer surgeon burden, not control, Surgeon-Guided Autonomy envisions intelligent systems that translate surgeon-defined intent into action across surgical planning, execution and recovery while preserving the surgeon's expertise, judgment and control.

The introduction will take place during Zimmer Biomet's sponsored symposium: The Future Is Now — From Kinematic Alignment to Intelligent Surgery at the Annual Meeting of the American Association of Hip and Knee Surgeons (AAHKS). The symposium will address topics of the unmet needs in orthopedics, share an integrated kinematic alignment philosophy in practice and introduce Surgeon-Guided Autonomy, alongside its new framework: Predict. Perform. Recover.

The company will also introduce a new awareness campaign: Surgeon-Guided Autono_Me_. The intentional spelling emphasizes the campaign's focus on intelligent surgical systems that put the surgeon at the center and work toward one outcome: more autonomy for the surgeon, not from the surgeon.

"Surgeon-Guided Autonomy reflects what we believe the relationship between surgeons and technology should be," said Jonathan Vigdorchik, M.D., Chief Science, Technology and Medical Affairs Officer at Zimmer Biomet. "For surgeons, it means intelligent technology that takes on more of the cognitive and physical work, so they can focus their expertise on the decisions only they can make. For patients, it means a surgeon whose full attention is on them, supported by intelligent surgical systems designed to facilitate decision making and help carry out their surgical plan, case after case. This is bigger than any single robotic platform. It's our vision for connecting intelligence, robotics and data across the entire care journey to empower surgeons, never replace them. We believe that's where orthopedics is heading, and Zimmer Biomet intends to lead the way."

The new category

The philosophy of Surgeon-Guided Autonomy inverts the traditional relationship between surgeons and their OR technology. It puts the surgeon where they should be, at the center, instead of asking surgeons to do more around technology. The vision is that with Surgeon-Guided Autonomy, intelligent surgical systems should take on more of the burden, translating clinical intent into action across planning, execution and recovery, while preserving surgeon judgment and control.

To meet Zimmer Biomet's definition of Surgeon-Guided Autonomy, the technology should:

  • Understand surgeon intent;
  • Execute on behalf of the surgeon;
  • Keep the surgeon in command and control;
  • And create a learning loop, connecting what happens in surgery to how patients recover, so each case can inform the next plan.

Zimmer Biomet's Vision for the Category Framework:

Surgeon-Guided Autonomy is built around three connected moments in the care journey, linked in one continuous loop:

  • Predict — Know where you're going before you begin. Autonomously analyze patient-specific data, simulate surgical options and recommend personalized plans aligned with the surgeon's goals and patient expectations.
  • **Perform —**Translate the surgeon's plan into autonomous execution of defined surgical tasks, with continuous monitoring and surgeon oversight.
  • Recover — Autonomously analyze recovery data, identify patients deviating from expected progress and deliver actionable insights to the care team—while informing future surgical planning.

"Today, planning, surgery and recovery too often live in separate silos, and the surgeon is left to connect them," said Dr. Nicolas Piuzzi, Cleveland Clinic. "To address the disconnected systems and bring surgeons into the conversation, Zimmer Biomet created Surgeon-Guided Autonomy, a category that asks surgeons to rethink what technology should take on and what should stay in our hands. Surgeon-Guided Autonomy treats them as one continuous loop, so what we learn from each recovery can shape the next plan. Surgeons and health systems don't have to wait to start building a more connected practice. I use many of the building blocks available from Zimmer Biomet today: ROSA® Knee with OptimiZe™, Persona® Knee System, ZB_Edge_® Analytics and mymobility® Care Management Platform."

This is just the beginning! To follow the conversation, visit surgeonguided.com .

EDITOR'S NOTE:

Booth #608  — Through the weekend, you can explore Surgeon-Guided AutonoMe and Predict. Perform. Recover. alongside Zimmer Biomet's hip and knee portfolio, including ROSA® Knee with OptimiZe™, TMINI® Miniature Robotic System, OrthoGrid HipAI®, ZB_Edge_® Analytics, mymobility® Care Management Platform and Persona IQ® The Smart Knee® along with the Persona®, Z1® and G7® Systems.

TMINI Miniature Robotic System is a registered trademark of THINK Surgical, Inc.

Persona IQ: The objective kinematic data provided by the CSE and CTE with CHIRP System are not intended to support clinical decision-making and have not been shown to provide any clinical benefit.

About Zimmer Biomet

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

On November 5, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “EUR Underwriting Agreement”) with Barclays Bank PLC, Citigroup Global Markets Limited, HSBC Bank plc, Morgan Stanley & Co. International plc and RBC Europe Limited, as representatives of the underwriters named therein (collectively, the “EUR Underwriters”), in connection with the public offering of €500.0 million aggregate principal amount of the Company’s 4.375% notes due 2033 (the “EUR Notes”). Also on November 5, 2026, the Company entered into an underwriting agreement (the “USD Underwriting Agreement” and, together with the EUR Underwriting Agreement, the “Underwriting Agreements”) with Barclays Capital Inc., BofA Securities, Inc., J.P. Morgan Securities LLC, Mizuho Securities USA LLC and SMBC Nikko Securities America, Inc., as representatives of the underwriters named therein (collectively, the “USD Underwriters” and, together with the EUR Underwriters, the “Underwriters”), in connection with the public offering of $500.0 million aggregate principal amount of the Company’s 5.850% notes due 2036 (the “USD Notes” and, together with the EUR Notes, the “Notes”).

On November 4, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

Prompts

Zimmer Biomet Holdings, Inc. (ticker ZBH), listed in United States.

Company History

Date Change Detail
May 10, 2016 Acquired Acquired LDR Holding Corp (CIK 1348324). Its filings from before the deal are on its own company page, not shown here.
May 26, 2015 Renamed ZIMMER HOLDINGS INC → ZIMMER BIOMET HOLDINGS, INC.

ETFs Holding Zimmer Biomet Holdings, Inc.

ETF Weight in ETF Shares Market value As of
LGHT 3.75% 1,078 $ 92.805K Jun 30, 2026
BSMC 2.17% 41,884 $ 3.606M Jun 30, 2026
JHAC 1.50% 617 $ 53.118K Jun 30, 2026
BMED 1.47% 2,076 $ 210.527K Nov 16, 2026
JDOC 1.01% 981 $ 100.15K Nov 17, 2026
CVAR 0.94% 4,287 $ 402.678K Jul 31, 2026
ABCS 0.69% 857 $ 85.734K Aug 31, 2026
HWSM 0.50% 160 $ 13.774K Jun 30, 2026
ITAN 0.48% 5,829 $ 595.083K Nov 17, 2026
UPSD 0.47% 5,916 $ 555.69K Jul 31, 2026
SOVF 0.41% 3,781 $ 355.149K Jul 31, 2026
MCDS 0.36% 275 $ 28.075K Nov 17, 2026
IALT short -0.35% -276,535 $ -28.043M Nov 16, 2026
SHRT 0.35% 449 $ 45.533K Nov 17, 2026
LVDS 0.27% 3,171 $ 323.727K Nov 17, 2026
BAMV 0.24% 2,787 $ 278.811K Aug 31, 2026
AIVL 0.22% 10,843 $ 933.474K Jun 30, 2026
AVMC 0.21% 11,194 $ 1.135M Nov 16, 2026
GVLU 0.17% 4,304 $ 436.469K Nov 17, 2026
MKTN short -0.16% -1,953 $ -168.134K Jun 30, 2026
VFVA 0.16% 15,020 $ 1.503M Aug 31, 2026
FTLS short -0.13% -32,176 $ 0.00 Nov 16, 2026
PINK 0.13% 4,191 $ 427.859K Nov 17, 2026
INRO 0.10% 5,869 $ 595.175K Nov 16, 2026
CAPE 0.08% 2,160 $ 185.954K Jun 30, 2026
DFUV 0.08% 116,081 $ 12.137M Nov 12, 2026
DXUV 0.06% 36,460 $ 3.812M Nov 12, 2026
DFSU 0.05% 12,519 $ 1.309M Nov 12, 2026
DFAC 0.05% 429,328 $ 44.891M Nov 12, 2026
EBI 0.04% 2,857 $ 285.814K Aug 31, 2026
XMAG 0.04% 911 $ 95.254K Nov 13, 2026
AVSU 0.04% 1,900 $ 192.679K Nov 16, 2026
AVLC 0.04% 5,853 $ 593.553K Nov 16, 2026
SFGV 0.04% 4,249 $ 430K Nov 18, 2026
DCOR 0.04% 167,480 $ 17.512M Nov 12, 2026
DFLV 0.04% 28,413 $ 2.971M Nov 12, 2026
DFAU 0.04% 44,332 $ 4.635M Nov 12, 2026
MODL 0.04% 4,255 $ 366.313K Jun 30, 2026
NTSD 0.04% 146 $ 12.569K Jun 30, 2026
DFUS 0.03% 61,479 $ 6.428M Nov 12, 2026
GDE 0.03% 1,228 $ 122.849K Aug 31, 2026
HCMT 0.02% 1,351 $ 126.899K Jul 31, 2026
ACVF 0.02% 350 $ 32.876K Jul 31, 2026
AVUS 0.02% 35,087 $ 3.558M Nov 16, 2026
AAUS 0.02% 814 $ 80K Nov 18, 2026
NTSX 0.02% 3,092 $ 266.19K Jun 30, 2026
VOXP 0.02% 12 $ 1,127.16 Jul 31, 2026
CSHP 0.01% 266 $ 26.975K Nov 16, 2026
GSPY 0.01% 710 $ 72.001K Nov 17, 2026
APUE 0.01% 1,746 $ 174.67K Aug 31, 2026
DYNF 0.00% 80 $ 8,112.80 Nov 16, 2026
CORO 0.00% 120 $ 12.199K Nov 16, 2026
THRO 0.00% 14 $ 1,419.74 Nov 16, 2026